Simvastatin with or without Ezetimibe in Familial Hypercholesterolemia
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Ezetimibe, a cholesterol-absorption inhibitor, reduces levels of low-density lipoprotein (LDL) cholesterol when added to statin treatment. However, the effect of ezetimibe on the progression of atherosclerosis remains unknown. METHODS: We conducted a double-blind, randomized, 24-month trial comparing the effects of daily therapy with 80 mg of simvastatin either with placebo or with 10 mg of ezetimibe in 720 patients with familial hypercholesterolemia. Patients underwent B-mode ultrasonography to assess the intima-media thickness of the walls of the carotid and femoral arteries. The primary outcome measure was the change in the mean carotid-artery intima-media thickness, which was defined as the average of the means of the far-wall intima-media thickness of the right and left common carotid arteries, carotid bulbs, and internal carotid arteries. RESULTS: The primary outcome, the mean (+/-SE) change in the carotid-artery intima-media thickness, was 0.0058+/-0.0037 mm in the simvastatin-only group and 0.0111+/-0.0038 mm in the simvastatin-plus-ezetimibe (combined-therapy) group (P=0.29). Secondary outcomes (consisting of other variables regarding the intima-media thickness of the carotid and femoral arteries) did not differ significantly between the two groups. At the end of the study, the mean (+/-SD) LDL cholesterol level was 192.7+/-60.3 mg per deciliter (4.98+/-1.56 mmol per liter) in the simvastatin group and 141.3+/-52.6 mg per deciliter (3.65+/-1.36 mmol per liter) in the combined-therapy group (a between-group difference of 16.5%, P<0.01). The differences between the two groups in reductions in levels of triglycerides and C-reactive protein were 6.6% and 25.7%, respectively, with greater reductions in the combined-therapy group (P<0.01 for both comparisons). Side-effect and safety profiles were similar in the two groups. CONCLUSIONS: In patients with familial hypercholesterolemia, combined therapy with ezetimibe and simvastatin did not result in a significant difference in changes in intima-media thickness, as compared with simvastatin alone, despite decreases in levels of LDL cholesterol and C-reactive protein. (ClinicalTrials.gov number, NCT00552097 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although the earlier ENHANCE trial could not confirm that an addition of ezetimibe to statins significantly reduces intima-media thickness in patients with familial hypercholesterolemia, the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
In the citing paper
“the SHARP and SEAS trials highlight ezetimibe’s role in the prevention of ischaemic cardiovascular events [62–65].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [65]
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Self-citationBots, M. L., Hoes, A. W., Koudstaal, P. J., Hofman, A., & Grobbee, D. E. (1997) · Circulation · doi:10.1161/01.cir.96.5.1432 · Cited by 2,345
Self-citationNiemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,577
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Self-citationBuchwald, H., Varco, R. L., Matts, J. P., Long, J. M., Fitch, L. L., Campbell, G. S., Pearce, M. B., Yellin, A. E., Edmiston, W. A., Smink, R. D., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199010043231404 · Cited by 1,001
Smilde, T., van Wissen, S., Awollersheim, H., Trip, M., Kastelein, J., & Stalenhoef, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04053-8 · Cited by 918
Self-citationTaylor, A. J., Sullenberger, L. E., Lee, H. J., Lee, J. K., & Grace, K. A. (2004) · Circulation · doi:10.1161/01.cir.0000148955.19792.8d · Cited by 890
The safety of statins in clinical practice
Armitage, J. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60716-8 · Cited by 833
Cited by
Items 601–700 of 1,000
Preliminary Observations From Preliminary Trial Results: Have We Finally Had Enough?
Taylor, A. J., & Nissen, S. E. (2008) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.108.811901 · Cited by 13
Novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors: a patent review
Pfefferkorn, J. A. (2011) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2011.547478 · Cited by 13
“Somewhat surprisingly, the recent ENHANCE (ezetimibe and simvastatin in hypercholesterolemia enhances atherosclerosis regression) and ARBITER 6-HALTS (arterial biology for the investigation of the treatment effects of reducing cholesterol 6: HDL and LDL treatment strategies in atherosclerosis) trials revealed that a s…”
BackgroundEzetimibe and Reactive Oxygen Species
Yamaoka‐Tojo, M., Tojo, T., Takahira, N., Masuda, T., & Izumi, T. (2010) · Current Vascular Pharmacology · doi:10.2174/157016111793744652 · Cited by 13
“In previous studies, ezetimibe effectively and safety reduces blood LDL-cholesterol with both monotherapy and combination therapy [12-14].”
Deharo, P., Pankert, M., Quilici, J., Grosdidier, C., Verdier, V., Bonnet, G., Morange, P., Alessi, M., Bonnet, J., & Cuisset, T. (2014) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2014.04.018 · Cited by 13
Shaw, S. M., Najam, O., Khan, U. A., Yonan, N. A., Williams, S. G., & Fildes, J. E. (2009) · Transplant Immunology · doi:10.1016/j.trim.2009.03.001 · Cited by 14
Antibodies to PCSK9: A Superior Way to Lower LDL Cholesterol?
Maxwell, K. N., & Breslow, J. L. (2012) · Circulation Research · doi:10.1161/circresaha.112.275859 · Cited by 18
HPS2-THRIVE results: Bad for niacin/laropiprant, good for ezetimibe?
Masana, L., Cabré, A., & Plana, N. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.06.006 · Cited by 12
“The data obtained from this study, which included a large number of patients for an adequate follow-up period, counterbalance dubious results from previous ezetimibe studies [1,2] lining up others [3].”
ResultAtherosclerotic cardiovascular disease in hyperalphalipoproteinemia due to LIPG variants
Cole, J., Blackhurst, D. M., Solomon, G. A. E., Ratanjee, B. D., Benjamin, R. L., & Marais, A. D. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.12.007 · Cited by 12
Self-citationLi, H., Xu, X., Lu, L., Sun, R., Guo, Q., Chen, Q., Wang, J., He, Z., & Zhang, Y. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03113-0 · Cited by 13
Sarkar, P., & Chattopadhyay, A. (2023) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.3c00472 · Cited by 12
Lv, X., Liu, X., Peng, Y., Li, W., Wang, J., Chen, X., Lei, J., Tang, C., Luo, S., Cai, Y., et al. (2024) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2024.107647 · Cited by 12
Correa, V., Gus, M., & Fuchs, F. D. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.59 · Cited by 13
Risk factors for cerebrovascular and cardiovascular diseases beyond age 75 years
Mostafaie, N., Huber, K., Sebesta, C., Krampla, W., Jungwirth, S., Zehetmayer, S., Hinterberger, M., Krugluger, W., Tragl, K., & Fischer, P. A. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0466-8 · Cited by 12
“The ENHANCE study led by Merck et al. (Kastelein et al. 2008) found that the treatment with statins did not perform well in slowing plaque formation in cardiac arteries.”
Effect of Electronic Prescription on Attainment of Cholesterol Goals
Michelis, K. C., Hassouna, B., Owlia, M., Kelahan, L. C., Young, H. A., & Choi, B. G. (2011) · Clinical Cardiology · doi:10.1002/clc.20861 · Cited by 13
Doggrell, S. A. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.696098 · Cited by 13
“In ENHANCE, ezetimibe was compared with placebo in subjects with familial hypercholesterolemia, and shown to have no effect on the intima--media thickness of the carotid artery [46].”
BackgroundMethodInfluentialLauridsen, B. K., Stender, S., Frikke‐Schmidt, R., Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2017) · International Journal of Epidemiology · doi:10.1093/ije/dyx096 · Cited by 12
The Saturated Fat, Cholesterol, and Statin Controversy A Commentary
Sinatra, S. T., Teter, B. B., Bowden, J., Houston, M. C., & Martínez‐González, M. Á. (2014) · Journal of the American College of Nutrition · doi:10.1080/07315724.2014.878633 · Cited by 13
“The administration of two drugs with different mechanisms of action in the same patient result in a drastic reduction of cholesterol levels but significant reductions in LDL levels achieved with both Zocor (41%) and Vytorin (58%), artherosclerosis progressed as the measurement in carotid intima-media thickness (IMT) i…”
BackgroundAn Emerging Paradigm in Atherosclerosis: Focus on Subclinical Disease
Miller, M. J. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.03.1976 · Cited by 14
Percutaneous Coronary Intervention in Familial Hypercholesterolemia Is Understudied
Ungar, L. D. J., Sanders, D. S., Becerra, B., & Barseghian, A. (2018) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00116 · Cited by 12
“If this goal is not achieved with statin therapy alone, ezetimibe can be added (28, 29).”
BackgroundFamilial Hypercholesterolemia☆
Maio, A., & Dowd, F. J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.05022-4 · Cited by 12
Montecucco, F., Quercioli, A., & Mach, F. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903282745 · Cited by 12
“[19] 2008 338 Simvastatin (80 mg/day) versus simvastatin (80mg/day) plus ezetimibe (10 mg/day) for 24 months Familial hypercholesterolemia Ezetimibe/simvastatin induced a significant reduction in LDL-C and CRP levels but no changes in the carotid and femoral artery IMT”
InfluentialLDL-C-Lowering therapy: Current and future therapeutic targets
Visser, M. E., Jakulj, L., Kastelein, J. J. P., & Stroes, E. S. G. (2008) · Current Cardiology Reports · doi:10.1007/s11886-008-0080-7 · Cited by 13
Self-citationTomlinson, B., Chan, P., Zhang, Y., & Lam, C. W. K. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1801638 · Cited by 11
The safety and efficacy of Ezetimibe Plus Statins on ASVD and Related Diseases
Wan, S., Ding, Y., Ji, X., & Meng, R. (2021) · Aging and Disease · doi:10.14336/ad.2021.0412 · Cited by 11
“Many clinical trials showed that ezetimibe plus statins did not yield consecutive elevation in AST or ALT ≥3 times ULN [16, 36, 37, 39, 44, 54, 58].”
BackgroundInfluentialChien, K., Tu, Y., Hsu, H., Su, T., Lin, H., Chen, M.-F., & Lee, Y. (2012) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-12-66 · Cited by 11
“Change in blood pressure seems to have a stronger effect on IMT than change in LDL cholesterol, suggesting the effects of lipid-lowering treatment on carotid IMT regression might be small [34].”
BackgroundHiro, T., Hirayama, A., Ueda, Y., Komatsu, S., Matsuoka, H., Takayama, T., Ishihara, M., Hayashi, T., Saito, S., & Kodama, K. (2014) · Journal of Cardiology · doi:10.1016/j.jjcc.2014.02.026 · Cited by 11
Liu, B., Che, W., Yan, H., Zhu, W., & Wang, H. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.0731 · Cited by 11
“Treatment with ezetimibe combined with a statin did not alter the progression of carotid artery intima-media thickening, despite a further reduction in the LDL-C and hsCRP levels, compared with that achieved with statins alone (28).”
ResultTreatment of dyslipidaemia in childhood
Kusters, D. M., Vissers, M. N., Wiegman, A., Kastelein, J. J. P., & Hutten, B. A. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656561003592169 · Cited by 12
“Recently, ezetimibe was the cause of some controversy, since in a large trial in adults, despite a significant lipid-lowering effect, no improvement on intimamedia thickness (IMT) was observed [37].”
BackgroundSelf-citationEzetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia
Lyseng-Williamson, K. A. (2012) · American Journal of Cardiovascular Drugs · doi:10.2165/11209150-000000000-00000 · Cited by 11
Diabetic dyslipidemia and cardiovascular risk
Eckel, R. H. (2008) · Current Diabetes Reports · doi:10.1007/s11892-008-0072-4 · Cited by 12
“Will ezetimibe reduce events despite not changing carotid intima-media thickness [ 20 ], and will the modest glucose-lowering effect of bile acid sequestrants [21] add benefi t to the LDL cholesterol–lowering effect of this drug class? In the fi eld of lipids, lipoproteins, diabetes, and CVD risk reduction, an aggress…”
BackgroundPCSK9 inhibitors in the current management of atherosclerosis
Whayne, T. F. (2016) · Archivos de cardiología de México · doi:10.1016/j.acmx.2016.11.013 · Cited by 11
Lipid Optimization in Lower Extremity Peripheral Arterial Disease
Sucharitkul, P. P. J., Jones, K. L., Scott, D. J. A., & Bailey, M. A. (2021) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2021.03.055 · Cited by 12
Lipid lowering therapy in type 2 diabetes
Föger, B. (2011) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-011-0908-4 · Cited by 11
“biology in 2 recent carotid IMT studies [34, 35].”
Chu, A. Y., Giulianini, F., Barratt, B. J., Ding, B., Nyberg, F., Mora, S., Ridker, P. M., & Chasman, D. I. (2015) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000962 · Cited by 11
Yoon, H. E., Song, J. C., Hyoung, B. J., Hwang, H. S., Lee, S., Jeon, Y. J., Choi, B. S., Kim, Y., & Yang, C. W. (2009) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2009.24.3.233 · Cited by 12
“The incremental lipid-lowering effect of ezetimibe has been observed in both non-transplant [8-18] and renal transplant”
BackgroundClemens, K. K., Shariff, S. Z., McArthur, E., & Hegele, R. A. (2018) · Lipids in Health and Disease · doi:10.1186/s12944-017-0649-5 · Cited by 11
“simvastatin plus ezetimibe on the progression of atherosclerosis in patients with familial hypercholesterolemia, as measured by carotid intima-media thickness [12].”
Lee, J., Lee, S. H., Kim, H., Lee, S., Cho, J., Lee, H., Yim, H. W., Yoon, K., Kim, H., & Kim, J. H. (2020) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.13271 · Cited by 13
Schneeweiß, S. (2009) · Value in Health · doi:10.1111/j.1524-4733.2009.00607.x · Cited by 12
Varespladib: targeting the inflammatory face of atherosclerosis
Arsenault, B. J., Boekholdt, S. M., & Kastelein, J. J. P. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq385 · Cited by 11
Self-citationKrumholz, H. M. (2010) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959577 · Cited by 11
Atherosclerosis and lipoprotein metabolism
Rang, H. P., Dale, M. M., Ritter, J., & Flower, R. J. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-06911-6.50025-6 · Cited by 10
First Iranian guidelines for the diagnosis, management, and treatment of hyperlipidemia in adults
Bagherikholenjani, F., Shahidi, S., Vaseghi, G., Ashoorion, V., Sarrafzadegan, N., Siavash, M., Heidarpour, M., Shahidi, S., Sadeghi, M., Mohammadifard, N., et al. (2024) · Journal of Research in Medical Sciences · doi:10.4103/jrms.jrms_318_23 · Cited by 11
“The results of these studies showed a favorable safety profile and a 50% greater reduction in LDL‑C. [106,107] The strategy of adding ezetimibe to statins before adding PCSK9 inhibitors is recommended because ezetimibe is a widely‑available generic drug, its safety and tolerability have already…”
BackgroundGupta, M., Szmitko, P. E., Tsigoulis, M., Braga, M. F. B., Kajil, M., Herjikaka, S., Quan, A., Teoh, H., & Verma, S. (2010) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0b013e3181e7fd74 · Cited by 10
Toward Individualized Cholesterol-Lowering Treatment in End-Stage Renal Disease
Silbernagel, G., Baumgärtner, I., Wanner, C., & März, W. (2014) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2013.11.001 · Cited by 11
Yiu, K., Cheung, B. M. Y., & Tse, H. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543781003623223 · Cited by 11
“However, this study was stopped prematurely as the steering committee believed that thepatientpopulationbeing studied inACHIEVE was no longer the correct population to test the primary study hypothesis of atherosclerosis progression as in the Effect of Combination Ezetimibe and High-Dose Simvastatin versus Simvastatin…”
BackgroundDunn, A. G., Bourgeois, F. T., Murthy, S., Mandl, K. D., Day, R. O., & Coiera, E. W. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.279 · Cited by 10
Oosterveer, D. M., Versmissen, J., Schinkel, A. F. L., Langendonk, J. G., Mulder, M. T., & Sijbrands, E. J. G. (2010) · Clinical Lipidology · doi:10.2217/clp.10.9 · Cited by 12
Self-citationBlackstock, O. J., Wang, K., & Fiellin, D. A. (2011) · Journal of General Internal Medicine · doi:10.1007/s11606-011-1807-5 · Cited by 10
Combination therapy for dyslipidemia
Sharma, M. (2011) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283499ef1 · Cited by 10
Bramlage, P., Lanzinger, S., Rathmann, W., Gillessen, A., Scheper, N., Schmid, S. M., Kaltheuner, M., Seufert, J., Danne, T., & Holl, R. W. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12783 · Cited by 11
Bays, H. E., Patel, M. D., Mavros, P., Ramey, D. R., Tomassini, J. E., Tershakovec, A. M., & Baxter, C. A. (2017) · Journal of clinical lipidology · doi:10.1016/j.jacl.2017.04.121 · Cited by 10
Applying the ordinal model of atherosclerosis to imaging science: a brief review
Groenendyk, J., & Mehta, N. N. (2018) · Open Heart · doi:10.1136/openhrt-2018-000861 · Cited by 10
“32 CIMT has documented use as an endpoint in clinical intervention trials.(33) 34 Additionally, meta-analysis of 37 197 patients by Lorenz et al(35) showed that adjusted risk of future MI increases by about 10% for every 0.”
MethodChan, D. C., Pang, J., & Watts, G. F. (2016) · Springer eBooks · doi:10.1007/978-3-319-11251-0_30 · Cited by 11
Savarese, G., Rosano, G. M. C., Parente, A., D’Amore, C., Reiner, M. F., Camici, G. G., Trimarco, B., & Filardi, P. P. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.028 · Cited by 10
Lipoprotein Metabolism and the Treatment of Lipid Disorders
Freeman, M. W., & Walford, G. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00041-x · Cited by 13
Clinical Pharmacology, Biomarkers and Personalized Medicine: Education Please
Koning, P. D., & Keirns, J. J. (2009) · Biomarkers in Medicine · doi:10.2217/bmm.09.53 · Cited by 11
The effect of ezetimibe on adipose tissue hormones in patients with isolated hypercholesterolemia
Krysiak, R. G., Żmuda, W., & Okopień, B. (2014) · Pharmacological Reports · doi:10.1016/j.pharep.2014.03.006 · Cited by 10
“However, in other trials, ezetimibe did not result in a regression of carotid artery atherosclerosis in patients with familial hypercholesterolemia [7] and in patients with coronary artery disease or its equivalent [8], as well as it did not reduce the composite outcome of combined aortic-valve events and ischemic eve…”
ResultTsoukas, M. A., & Mantzoros, C. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00037-8 · Cited by 12
Is Carotid Intima-Media Thickness a Reliable Clinical Predictor?
Spence, J. D. (2008) · Mayo Clinic Proceedings · doi:10.4065/83.11.1299 · Cited by 10
Huang, P., Chen, J.-Y., Chen, C., Chen, J., Lin, S., & Shih, C.-C. (2016) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2014.11.088 · Cited by 9
Yang, M., Jiao, H., Li, Y., Zhang, L., Zhang, J., Zhong, X., & Xue, Y. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s372143 · Cited by 11
“statins.(13) The proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibody significantly reduces serum LDL-C.”
BackgroundFamilial Hypercholesterolemia: From Clinical Suspicion to Novel Treatments
Mirzai, S., Chevli, P. A., Rikhi, R. R., & Shapiro, M. D. (2023) · Reviews in Cardiovascular Medicine · doi:10.31083/j.rcm2411311 · Cited by 11
“An additional 20% LDL-C reduction can be expected by adding ezetimibe to statin therapy in FH patients [61–63].”
BackgroundNovel Treatments for Familial Hypercholesterolemia: Pharmacogenetics at Work
Marbach, J. A., McKeon, J. L., Ross, J. L., & Duffy, D. (2014) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1441 · Cited by 12
“27 Despite the favorable decrease in LDL-C with combination therapy, there was no difference between groups in the primary end point, change in carotid intima-media thickness.(28) Ezetimibe alone has not been shown to decrease long-term cardiovascular outcomes.”
BackgroundMedical Management of Stable Coronary Atherosclerosis
Pellicori, P., Costanzo, P., Joseph, A. C., Hoye, A., Atkin, S. L., & Cleland, J. G. F. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0313-0 · Cited by 10
“The ENHANCE trial looked at combination treatment of simvastatin and ezetimibe versus simvastatin alone in patients with familial hypercholesterolemia, and showed that the rate of progression of atherosclerosis in carotid intima–media thickness (CIMT) was not statistically different after 24 months of follow-up [57].”
Pharmacotherapy of dyslipidemias in the adult population
Vigna, G. B., & Fellin, R. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.513116 · Cited by 9
“In the ENHANCE study [70] and in the ARBITER 6-HALTS trial [71], which have been blamed for methodological deficiencies [72], simvastatin plus ezetimibe were not winning strategies in controlling the progression of carotid intimalmedial thickness (CIMT), while other investigations showed an effect on CIMT that was con…”
ResultSample size requirements in trials using repeated measurements and the impact of trial design
Peters, S. A. E., Palmer, M. K., den Ruijter, H. M., Grobbee, D. E., Crouse, J. R., O’Leary, D. H., Evans, G. W., Raichlen, J. S., & Bots, M. L. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.678937 · Cited by 9
Self-citationZhao, X., Song, L., Wang, Y., Li, J., Zhou, J., Chen, R., Liu, C., Zhou, P., Sheng, Z., Chen, Y., et al. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s334246 · Cited by 9
Langslet, G., Holven, K. B., & Bogsrud, M. P. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab228 · Cited by 9
Padhy, B., Yadav, R., & Gupta, Y. K. (2013) · Singapore Medical Journal · doi:10.11622/smedj.2013031 · Cited by 9
Lewandowski, J., Siński, M., Puchalska, L., Symonides, B., & Gaciong, Z. A. (2014) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2014.06.003 · Cited by 9
Kumar, S., Lahey, K. A., Day, A. G., & LaHaye, S. A. (2009) · Lipids in Health and Disease · doi:10.1186/1476-511x-8-56 · Cited by 9
Rosuvastatin and progression of atherosclerosis
Nicholls, S. J. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.7.925 · Cited by 9
Feng, T., Xiaoxing, H., Liang, Q., Liang, Y., Yuan, Y., Feng, L., Wu, W., Xiao, X., & Han, Y. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.01.013 · Cited by 9
Ahn, S. B., Jun, D. W., Jang, K., Lee, B. H., & Shin, K. J. (2018) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2017.100 · Cited by 9
“However, a recent randomized controlled study on NAFLD revealed that ezetimibe did not improve fatty liver [20].”
BackgroundJarauta, E., Bea, A. M., Marco-Benedí, V., & Lamíquiz-Moneo, I. (2020) · Frontiers in Genetics · doi:10.3389/fgene.2020.554931 · Cited by 9
“The addition of ezetimibe to statins for the treatment of HC has been shown equally effective in decreasing LDL-C in FH children and adults (Kastelein et al., 2008; Kusters et al., 2015).”
BackgroundMasson, W. M., Corral, P., Barbagelata, L., Cobo, A. L., Nogueira, J. P., Siniawski, D. A., & Ray, K. K. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.07.004 · Cited by 9
Kinouchi, K., Ichihara, A., Bokuda, K., Morimoto, S., & Itoh, H. (2012) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.14860 · Cited by 9
Lipid Management in the Geriatric Patient
Nair, A. P., & Darrow, B. J. (2009) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2008.11.003 · Cited by 9
Clinical Relevance of Target Identity and Biology: Implications for Drug Discovery and Development
Patel, A. C. (2013) · SLAS DISCOVERY · doi:10.1177/1087057113505906 · Cited by 11
Lamprecht, D. G., Shaw, P. B., King, J. B., Hogan, K. N., & Olson, K. L. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.04.007 · Cited by 10
Sämann, A., & Wolf, G. (2012) · Der Internist · doi:10.1007/s00108-012-3129-z · Cited by 9
“Wenn im Einzelfall die Therapieziele (LDL <100 mg/dl) nach Ausdosieren des Statins nicht erreicht werden, ist die zusätzliche oder alternative Gabe von Fibraten, Ezetimib sowie retardierter Nikotinsäure nach aktueller Datenlage nicht zu empfehlen [41, 42, 43].”
BackgroundHoward, W. J. (2010) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.05.002 · Cited by 9
“The first challenge to the anti-atherosclerotic efficacy of ezetimibe came from the results of the ENHANCE Trial [9].”
ResultImaging outcomes in cardiovascular clinical trials
Razzouk, L., & Farkouh, M. E. (2009) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2009.104 · Cited by 9
“In this context, the ENHANCE (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) tria”
BackgroundToutouzas, P. K., & Richter, D. J. (2008) · Angiology · doi:10.1177/0003319708321748 · Cited by 9
Sanz, J., Moreno, P., & Fuster, V. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.12.047 · Cited by 10
Niacin Compared with Ezetimibe
Duivenvoorden, R., Vergeer, M., & Kastelein, J. J. P. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0912942 · Cited by 9
Self-citationLi, Y., Dávila-Velderrain, J., & Kellis, M. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/059345 · Cited by 9
Li, S., Liu, H., & Li, J. (2024) · Drugs · doi:10.1007/s40265-024-02113-5 · Cited by 9
Hiddink, L., Dallinga‐Thie, G. M., Hovingh, G. K., de Visser, M. C. H., Peer, P. G. M., Stalenhoef, A. F. H., & van Heerde, W. L. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.11.023 · Cited by 8
Self-citationCholesterol screening and statin use in children: a literature review
King, K. K., Macken, A. P., Blake, O., & O’Gorman, C. S. (2018) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-018-1835-9 · Cited by 9
Lose, J. M., Dorsch, M. P., & Bleske, B. E. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1222 · Cited by 9
Impact of Drug Policy on Regional Trends in Ezetimibe Use
Lu, L., Krumholz, H. M., Tu, J. V., Ross, J. S., Ko, D. T., & Jackevicius, C. A. (2014) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.114.001023 · Cited by 8
Exercise training in aging and diseases.
Conti, V., Russomanno, G., Corbi, G., & Filippelli, A. (2012) · PubMed Central · Cited by 11
Peters, S. A. E., Palmer, M. K., Grobbee, D. E., Crouse, J. R., Evans, G. W., Raichlen, J. S., & Bots, M. L. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328345d85e · Cited by 9
Self-citationFernández, A. B., Chaudhry, W., & Thompson, P. D. (2019) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-019-0798-0 · Cited by 8
Surrogate end‐points in clinical practice: are we providing worse care?
Martin, J. H., & Fay, M. F. (2010) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2010.02248.x · Cited by 8
Antilipidemic Drug Therapy Today and in the Future
Kramer, W. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_15 · Cited by 8
“Large clinical trials, however, like ENHANCE in patients with heterozygous FH did not reveal a statistically significant effect on carotid intima media thickness compared to simvastatin alone despite a higher LDL-C lowering efficacy of the combination (Kastelein et al. 2008).”
BackgroundNovel LDL-oriented pharmacotherapeutical strategies
Huang, L., & Zhu, H.-B. (2012) · Pharmacological Research · doi:10.1016/j.phrs.2012.01.007 · Cited by 9
Carotid intima-media Thickness and Cardiovascular Risk
Mookadam, F., Tanasunont, W., Jalal, U., Mookadam, M., & Wilansky, S. (2011) · Future Cardiology · doi:10.2217/fca.11.2 · Cited by 9
Current imaging modalities for atherosclerosis
Kataoka, Y., Uno, K., Puri, R., & Nicholls, S. J. (2012) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.12.28 · Cited by 10
Metadata
- Authors
- Kastelein, J. J. P., Akdim, F., Stroes, E. S. G., Zwinderman, A. H., Bots, M. L., Stalenhoef, A. F. H., Visseren, F. L. J., Sijbrands, E. J. G., Trip, M. D., Stein, E. A., Gaudet, D., Duivenvoorden, R., Veltri, E. P., Marais, A. D., & de Groot, E.
- Affiliations
- Amsterdam UMC Location University of Amsterdam (NL)
- University Medical Center Utrecht (NL)
- Radboud University Nijmegen (NL)
- Erasmus MC (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-04-03
- Volume
- 358
- Issue
- 14
- Pages
- 1431-1443
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2120289695
- Semantic Scholar
- 0da4a48a4d402878a4b01330a3e43a185140f586
- Cited by
- 1,241
- References
- 34
- Citations by year
- 2026: 8 · 2025: 13 · 2024: 16 · 2023: 20 · 2022: 14 · 2021: 24 · 2020: 27 · 2019: 35 · 2018: 30 · 2017: 38 · 2016: 50 · 2015: 77 · 2014: 91 · 2013: 85 · 2012: 111
- FWCI
- 210.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- simvastatin, ezetimibe, familial hypercholesterolemia, LDL cholesterol lowering, atherosclerosis progression, carotid intima-media thickness, femoral artery, cholesterol absorption inhibition, triglycerides, C-reactive protein, statin combination therapy, lipid-lowering therapy, atherosclerotic plaque regression
- MeSH terms
- Ezetimibe, Adult, Anticholesteremic Agents, Azetidines, Carotid Arteries, Cholesterol, Double-Blind Method, Drug Therapy, Combination, Female, Femoral Artery, Humans, Hyperlipoproteinemia Type II, Cholesterol, LDL, Male, Middle Aged, Triglycerides, Ultrasonography, Treatment Outcome, Tunica Intima, Tunica Media, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.